UP421 and SC451 are related research programs, not two names for the same treatment. UP421's reported human proof of concept used modified donor-derived islets. SC451 is a separate stem-cell-derived candidate using the related hypoimmune platform. 1 2
That distinction is essential when a headline about functioning cells without immunosuppression is interpreted as an available insulin-free stem-cell treatment.
What was reported in July 2026?
Sana's July 13 announcement describes a fourteen-month follow-up of an investigator-sponsored UP421 study and a corresponding NEJM letter. It reports continued insulin-producing cell function without immunosuppression in the participant, with circulating C-peptide and a meal-stimulated response. 1
Our source for that update is the developer's account. The underlying 2026 letter was not independently accessed in this research pass. The company's interpretation of safety and immune evasion should therefore remain attributed, not be presented as this publication's independent clinical certification.
Why this does not establish insulin independence
The announcement explicitly describes a low-dose proof-of-concept study whose purpose was not to demonstrate improved glycemia or reduced external insulin use. 1
That is the decisive distinction. Evidence that transplanted cells remain functional without immunosuppression addresses an important research obstacle. It does not establish that they supply enough insulin to replace the person's ongoing requirements.
A hypothetical comparison makes the logic clear: observing a functioning component is not the same as demonstrating that an entire system can perform the full required workload. This analogy is not a dosing claim. It explains why an endpoint should not be expanded beyond what the study was designed to show.
Where SC451 fits
Sana's August 2026 update describes preparations for SC451 clinical development. It is a stem-cell-derived candidate intended to pursue a more scalable version of the broader approach. The announcement does not turn UP421's donor-cell follow-up into a completed SC451 clinical result. 2
A platform relationship can justify scientific interest in another candidate. It does not transfer the human evidence automatically. A separate product still needs evidence about its own cells, manufacturing, dose, clinical outcomes and safety.
Why avoiding immunosuppression is a separate milestone
Conventional islet transplantation can require immune-suppressing medication, which brings its own burden and risks. NIDDK describes that trade-off in its transplant explanation. 3
A strategy that could protect transplanted cells without those medicines would therefore address a different problem from merely producing insulin-capable cells. That is why the UP421 observation matters even though it does not establish insulin independence.
The right interpretation is neither to overclaim a complete cure nor dismiss the observation because it did not answer a different endpoint.
How this differs from zimislecel and VX-264
Zimislecel's published clinical results concern stem-cell-derived islets given with immunosuppression. VX-264 was a separate cells-and-device program that was discontinued after an efficacy endpoint was not met. 4 5
These approaches belong in a comparison, but not a single success-rate table. Cell source, protection strategy, analyzed population and intended outcome differ. The islet comparison makes those differences explicit.
A discontinued encapsulation program also does not prove that immune-evasive modified cells cannot work. The reverse is equally important: an encouraging early modified-cell observation does not retroactively make every encapsulation strategy effective.
What the next evidence would need to show
For SC451, a clinical-start announcement, first participant treated, sustained cell function, insulin-use outcomes and longer safety follow-up would be separate events. We do not assign completed status to future company plans.
For UP421, more follow-up in the same person extends observation; additional independently assessed participants would address a different dimension of uncertainty. Both are useful, but neither should be disguised as the other.
Present conclusion
The reported UP421 follow-up is evidence about functional modified donor islets without immunosuppression in an early proof of concept, as described by the developer. It is not proof that an available SC451 treatment has made people universally insulin-independent. 1
The cell-therapy hub links the programs, while the insulin-independence page separates the endpoints that headlines often combine.